Browse Articles

Discover research articles across all indexed journals

Clinical significance of urotensin 2 plasma level in patients diagnosed with prostate cancer.

Journal of Clinical Oncology Cigdem Dinckal, Zeynep Gulsum Guc, Huriye Erbak Yilmaz et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.249

249 Background: Urotensin-II is a small somatostatin-like cyclic peptide characterized by its potent vasoconstrictor activity. Urotensin-II (UT-II) and its receptor (UTR) have been shown to play a role in the formation of different epithelial cancers. To date, many studies have been reported in prostate cancer that provide genetic contributions with diagnostic, prognostic and therapeutic potential for carcinogenesis. However, the role of urotensin-II in prostate carcinogenesis has not yet been elucidated. There are several limitations to using PSA as a biomarker in prostate cancer follow-up. More accurate and specific biomarkers are needed to improve diagnosis and monitoring of prostate cancer. Our study aimed to reveal the clinical importance of plasma UT-2 level in metastatic prostate cancer patients and to investigate its correlation and prognostic importance with clinical parameters such as PSA level and pathological parameters such as Gleason Score. Methods: Patients who applied to İzmir Katip Celebi University Atatürk Training and Research Hospital Medical Oncology Polyclinic in 2023 were included in our study. The demographic information of the patients was scanned from the oncology file system and recorded. Measurements of plasma ÜT-2 level were made by a biochemistry specialist at İzmir Katip Celebi University Atatürk Training and Research Hospital Biochemistry Laboratory. For the ELISA method, Urotensin 2 ELISA (Elabscience lot no: E-EL-2047) kit was used in the Biotek (ELx800, USA) semi-automatic ELISA device. Results: A total of 147 patients, 100 metastatic and 47 control groups, were included in our study. No statistically significant difference was observed between the groups in terms of additional diseases that may be related to UT-2 level: Diabetes Mellitus, hypertension, peripheral artery disease, coronary artery disease, chronic renal failure and smoking characteristics (p>0.05). When the PT-2 level was compared between the de-novo and non-de-novo metastasis groups and the control groups, both metastasis groups had a higher average than the control groups (p = 0.004). The cut-off value for UT-2 was determined as 1.269 ng/mL. UT-2 sensitivity, specificity, positive predictive value and negative predictive value were found to be 81%, 53%, 79% and 57%, respectively. Conclusions: Today, studies are continuing rapidly to increase the efficiency of PSA and to find new tumor markers. In our study, UT-2 levels in metastatic prostate cancer patients were found to be statistically higher than other groups. This is the first study in the literature to study the UT-2 plasma level in prostate cancer, and UT-2 may be an important biomarker in predicting prognosis in prostate cancer.

Association between combination of VI-RADS based on T2WI and morphological features and pathological outcome and prognosis in bladder cancer.

Journal of Clinical Oncology Shunsuke Ikuma, Jun Akatsuka, Hikaru Mikami et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.690

690 Background: VI-RADS is widely used to identify muscle-invasive bladder cancer (MIBC). However, it is not known whether structural category (SC; VI-RADS based on T2-weighted images) alone is useful in diagnosing clinicopathological features and prognosis of bladder cancer. This study investigates the diagnostic performance of SC in the detection of MIBC. We also measured tumour contact length (TCL), difference in signal intensity ratio (dSIR) and coefficient of variation (CV) within the tumour on T2WI. We evaluated whether these factors could improve the diagnostic performance of SC for MIBC and explored the correlation between these morphological features and clinicopathological characteristics and prognosis. Methods: Between August 2018 and July 2023, we performed 587 transurethral resections of bladder tumours. This study includes 236 patients who underwent preoperative MRI. We first evaluated the diagnostic performance of VI-RADS and SC for MIBC. TCL, dSIR and CV were measured on T2WI. The dSIR was defined as the difference between the signal intensity (SI) of the tumour and that of the underlying muscle layer, divided by the SI of the normal muscle layer. The CV was calculated as the standard deviation of the SI within the tumour divided by the mean SI. All patients were divided into high and low SC groups and the relationship between MIBC and TCL, dSIR and CV was examined. Cut-off values for the diagnosis of MIBC and overall survival (OS) were calculated based on ROC curves for the most correlated factors in each group, which were added to the SC score to evaluate the diagnostic value. We also examined the correlation between each factor and pathological findings. Results: The diagnostic performance of VI-RADS with a cut-off score of 4 was an AUC of 0.888. Meanwhile, the diagnostic performance of SC with a cut-off score of 4 was AUC of 0.885. The association between MIBC and each factor was compared in the SC≥4 and SC≤3 groups. In the SC≥4, multivariate analysis showed significant differences in dSIR (p<0.001). In the SC≤3, multivariate analysis showed TCL is significantly longer in MIBC (p<0.001). The diagnostic performance was an AUC of 0.912 for suspected MIBC with SC≥4 and dSIR<1.03 and SC≤3 and TCL≥36mm. In pathological features, TCL is significantly longer in high-grade (p=0.018), necrosis(p<0.001), variant(p=0.002), lymph node metastasis (p<0.001) and organ metastasis (p<0.035). Univariate COX analysis showed that SC≥4 was risk factors for OS (HR = 2.15, P = 0.031). In the SC≥4, patients with TCL≥40 mm had worse OS (HR = 3.06, P < 0.015). In the SC≤3, patients with TCL≥31 mm had worse OS (HR = 10.59, P < 0.001). Conclusions: The present study showed that SC combined with dSIR and TCL has good diagnostic performance for MIBC. We also found that TCL correlates with high-grade tumor, necrosis, and variant histology. The combination of SC and TCL effectively predicts OS in bladder cancer.

The CABOLD study: A real life prospective cohort evaluating the combination of cabozantinib and nivolumab among older patients with renal-cell carcinoma.

Journal of Clinical Oncology Maxime Frelaut, Natacha Naoun, Arnaud Pages et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps607

TPS607 Background: In the era of combination therapy, and due to age-related physiological changes, management of older patients with Clear-cell renal cell carcinoma (ccRCC) is a challenge. The combination of cabozantinib and nivolumab is one of the recommended treatments in untreated metastatic or locally advanced ccRCC. However, data regarding the use of this treatment among 70 years old or more (70+) patients are scarce. The CABOLD study seeks to address these gaps by assessing the real-life use of this combination in older patients. Methods: The CABOLD study is a prospective, multicentric, single-arm cohort trial conducted across 10 centers in France. It aims to enroll 50 patients aged 70 years and above with advanced or metastatic ccRCC, who are treatment-naïve in this setting. Eligible participants must have a Performance Status (PS) of 0 to 2. Patients will receive standard-of-care treatment consisting of cabozantinib at 40 mg daily and nivolumab on a 28-day cycle (240 mg on Days 1 and 15 for the first two cycles, followed by 480 mg on Day 1 for subsequent cycles). The starting dose of cabozantinib may be reduced to 20 mg daily at the investigator’s discretion. Patients will benefit of a multi-modal follow-up including medical oncologists, geriatricians and trained nurses to monitor safety closely. Abbreviated geriatric assessment, using G-CODE, will be performed at inclusion, under treatment, and during follow-up, along with quality of life (QoL) evaluation. Optional pharmacological monitoring for cabozantinib will be conducted to assess potential associations with clinical outcomes. Patients will be followed for 12 months in the study, followed by a long-term follow-up after one year. Primary objective is to describe real-life treatment patterns of nivolumab-cabozantinib, including dose modifications and interruptions due to toxicity. Main secondary objectives include efficacy, survival, tolerance, QoL. Enrollment for the study has not yet begun at the time of submission. The CABOLD study is designed to provide insights into the real-world use of cabozantinib and nivolumab in 70+ patients with metastatic ccRCC. By incorporating geriatric assessments and pharmacological monitoring, the trial aims to improve our understanding of treatment tolerability, efficacy, and quality of life in this vulnerable population, potentially guiding tailored therapeutic strategies for older adults with RCC.

Metastasis-directed treatment (MDT) for patients (pts) with non-clear cell renal cell carcinoma (nccRCC): Results from a matched 15-year retrospective cohort.

Journal of Clinical Oncology Rogerio Almeida Moreno Santos, Gabriel Berlingieri Polho, Vinicius Cruz Parrela et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.497

497 Background: nccRCC represents a diverse group of diseases with variable clinicopathological features. We aimed to evaluate the impact of MDT on clinical outcomes of pts with nccRCC. Methods: We reviewed our institutional database (São Paulo State Cancer Institute, University of São Paulo) to identify pts with ICD-C64 (kidney cancer) with nccRCC. Electronic medical records were reviewed to register the clinical and pathological features. Histological subtypes were classified as per the 2022 World Health Organization classification. MDT was considered as any focal treatment (surgery or radiation) given with non-palliative intent. Overall survival (OS) was calculated as the time from diagnosis of metastatic disease until death or last follow-up. Survival probabilities were estimated using the Kaplan-Meier method and compared via the log-rank test. To correct for imbalances between MDT recipients and non-recipients, we applied a propensity score matching based on the International Metastatic RCC Database Consortium (IMDC) classification, ECOG-PS, subtype, number of affected organs, and presence of sarcomatoid features in the primary tumor. Results: From September 2009 to January 2024, we identified 2,867 pts with kidney cancer. From 620 pts diagnosed with nccRCC, 143 (23.1%) had metastatic disease. Of these, MDT was administered to 39 pts. Clinicopathological features of pts treated with MDT vs. non-treated with MDT were described in the table. Most common MDT was surgery (n=30), followed by radiosurgery (n=9). MDT was associated with improved OS (HR 0.24, 95% CI 0.14-0.40, median 8.0 vs. 58.6 months), confirmed after propensity score matching (HR 0.31, 95% CI 0.17-0.56, median 17.5 vs. 58.6 months). In the matched cohorts, MDT was associated with increased OS in chromophobe (HR 0.33; 95% CI 0.08-1.29, median 23.3 vs. 69.3 months), papillary (HR 0.29; 95% CI 0.12-0.70, median 16.7 vs. 47.7 months), and unclassified subtypes (HR 0.16; 95% CI 0.04-0.66, median 3.1 vs. 18.9 months). Conclusions: This retrospective analysis suggests that a subset of pts with nccRCC may benefit from MDT, regardless of histological subtype. Clinicopathological features of pts treated with MDT vs. non-treated with MDT. Variable Overall Population (%) MDT (%) Non-MDT (%) Age (median) 57 53.8 57.3 T StageT1- T2T3-T4 25 (17)90 (62) 11 (28)22 (56) 14 (13)68 (64) IMDCFavorableIntermediatePoor 29 (20)64 (44)49 (34) 13 (33)19 (49)6 (15) 16 (15)45 (42)43 (40) ECOG0 – 1≥2 93 (64)42 (29) 32 (82)4 (10) 61 (57)38 (36) SubtypePapillary Chromophobe Collecting DuctAngiomyolipoma MIT Translocation Unclassified Others Medullary carcinoma 72 (49) 20 (13) 4 (3) 1 (1) 12 (8) 25 (17) 7 (5) 5 (3) 19 (48)9 (23)001 (3)8 (21)2 (5)0 53 (50)11 (10)4 (4)1 (1)11 (10)17 (16)5 (5)5 (5) MetastasisLungLiverCNSBone 59 (40)15 (10) 48 (33) 76 (52) 14 (36)13 (33)6 (15)13 (33) 62 (58)35 (33)9 (8)46 (43)

Exploring the potential of 2D PtTe2-based memristors for neuromorphic computing

Applied Physics Letters Xiaojuan Lian, Xin Zhang, Shiyu Li et al. Feb 10, 2025 DOI: 10.1063/5.0244591

Neuromimetic devices have emerged as transformative technologies with the potential to redefine traditional computing paradigms and enable advanced artificial neural systems. Among various innovative materials, two-dimensional (2D) materials have garnered attention as frontrunners for next-generation device fabrication. In this work, we report the fabrication and comprehensive characterization of a memristor based on 2D PtTe2. The device demonstrates exceptional performance metrics, including a high OFF/ON ratio, low switching voltage, and long data retention time. Leveraging density functional theory calculations, we unravel the underlying conduction mechanism, revealing the pivotal role of Ag conductive filaments in resistive switching behavior. Furthermore, the neuromorphic capabilities of the PtTe2 memristor were evaluated through its emulation of key brain-inspired synaptic functionalities, such as long-term depression/enhancement, paired-pulse facilitation, and spike-timing-dependent plasticity. By modulating its electrical conductance, we implemented a convolutional neural network for MNIST handwritten digit recognition, achieving a remarkable accuracy of 97.49%. To further illustrate its adaptive learning capabilities, we demonstrated a Pavlov's dog experiment using the device. This study establishes 2D PtTe2 as a promising material for neuromorphic applications and represents a critical step forward in bridging the gap between advanced materials and next-generation computing architectures. These findings lay a robust foundation for future exploration of PtTe2 in the field of neuromorphic engineering.

Lightweight mechanical equipment fault diagnosis framework based on GCGAN-MDSCNN-ICA model

Scientific Reports Longyi Liu, Yanqing Zhao, Yi Hu et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89576-y

Assessment of <i>PARP1</i> mRNA expression as prognostic of aggressive pathology and adverse outcomes, and as predictor of response to PARP inhibition in castration-sensitive prostate cancer.

Journal of Clinical Oncology Emmanuel S. Antonarakis, Mohammed Alshalalfa, Benjamin A. Teply et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.202

202 Background: While several PARP inhibitors are approved in combination with hormonal therapies for metastatic castrate resistant prostate cancer (CRPC), their use in castrate sensitive prostate cancer (CSPC) is understudied. We previously reported that olaparib monotherapy (without ADT) shows significant clinical activity in BRCA2 -altered patients with biochemically recurrent (BCR) prostate cancer. Here, we explored prognostic and predictive PARP-related mRNA biomarkers derived from primary prostate tumors. Methods: We characterized the expression of 16 PARP transcripts using a cohort of 52,266 radical prostatectomy (RP) specimens (2016-2024) undergoing Decipher prostate genomic classifier testing (Veracyte Inc). Transcriptome-wide mRNA expression data as well as baseline clinical/pathologic factors were retrieved from the Decipher GRID database (NCT02609269). Associations between high PARP expression (top 25%), baseline factors, and gene signatures were examined using logistic regression. We assessed the association between PARP expression and distant metastases in 3 retrospective cohorts (n= 545, 855, and 325). Finally, we evaluated PARP expression in our prior phase II trial (NCT03047135, n=39) of olaparib monotherapy in the setting of BCR following RP. Results: Higher mRNA levels of PARP1 , 2 , 8 and 14 showed strong associations (all P &lt;0.001) with known adverse prognostic factors such as very-high Decipher score (&gt;0.85), high Gleason grade (GG5) and non-organ confined disease (EPE, SVI and LNI), while higher PARP6 and 7 expression were associated with more favorable disease characteristics. High PARP1 expression was positively correlated with DNA-repair deficiency (r=0.77) and tumor immune microenvironment (r=0.62) signatures. In 3 independent retrospective cohorts of intermediate-high risk PCa patients, higher PARP1 expression was strongly associated with development of distant metastases after RP (HR 1.70, 1.81, and 1.67 respectively; all P &lt;0.05). Finally, in our phase II trial of patients with BCR who received olaparib monotherapy, PARP1 (but not PARP2 ) expression from RP was 1.5-fold higher in samples with BRCA2 mutations (median 0.416 vs 0.276, P =0.01) and was associated with overall improved PSA progression-free survival (continuous variable, HR 0.55, P =0.01) and longer time to next systemic treatment (continuous variable, HR 0.66, P =0.02). Conclusions: High PARP1 mRNA expression, measured at RP, is associated with aggressive disease biology and greater risk of metastasis. However, high PARP1 (but not PARP2 ) levels are associated with improved response to PARP inhibition in the setting of BCR prostate cancer. Future trials testing PARP (including PARP1-selective) inhibitors in the CSPC space should consider measuring PARP1 mRNA levels in addition to BRCA1/2 mutation status. Clinical trial information: NCT02609269 , NCT03047135 .

Phase II study of oral APL-1202 plus tislelizumab or tislelizumab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC).

Journal of Clinical Oncology Matthew D. Galsky, John P. Sfakianos, Dingwei Ye et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.793

793 Background: Interim results of the randomized phase II trial of neoadjuvant tislelizumab +/- oral APL-1202 (nitroxoline) revealed promising pathological complete response (pCR) rates and met prespecified thresholds for study expansion (ASCO GU 2024). Here, we report the final primary endpoint analysis of this trial. Methods: Patients with cT2-T4aN0M0 urothelial cancer of the bladder based on local assessment, planned for radical cystectomy (RC), and ineligible for or refusing cisplatin-based chemotherapy were eligible. Patients were randomly assigned to APL-1202 plus tislelizumab (A+T) or tislelizumab (T), stratified by PD-L1 expression. Neoadjuvant tislelizumab was administered q3weeks for 3 cycles and APL1202 was administered orally tid. The primary endpoint was centrally assessed (pCR, pT0N0) rate and secondary endpoints included central pathologic response (PaR, &lt; ypT2N0) rate and safety. Results: A total of 103 patients were enrolled; 28 patients declined RC after neoadjuvant treatment (A+T=16, T=12). Consequently, 75 patients remained in the efficacy analysis set (EAS); RC was completed after A+T in 42/43 patients and after T in 31/32 patients. The pCR and PaR results in the EAS are presented in the table. On retrospective central pathology review of baseline TURBT specimens, a large subset of patients were determined to be ineligible due to &lt;cT2 disease (33/75). There was a numerically higher pCR rate in an exploratory analysis of this retrospectively defined ‘protocol eligible’ subset (A+T: 9/22, T: 4/20). Treatment related adverse events (TRAEs) occurred in 35 (59%) on the A+T arm and 19 (44%) on the T arm. TRAEs (94%) were predominantly ≤ CTCAE grade 2. Conclusions: Neoadjuvant A+T in cisplatin-ineligible patients prior to RC was safe. Evaluation of the efficacy in MIBC is complicated by the large subset of patients enrolled retrospectively determined to have &lt;cT2 disease but pCR rates were similar between groups in the EAS. A signal of higher activity of A+T may be present in PD-L1 “low” tumors supporting further exploration of the immunomodulatory effects of A+T. Evaluation of efficacy is further complicated by a large subset of patients declining RC after neoadjuvant treatment underlining the need for novel bladder-sparing approaches. Clinical trial information: NCT04813107 . pCR rate, pT0N0 PaR rate, &lt; ypT2N0 EAS (n=75) n(%) A+T (n=43) T (n=32) A+T (n=43) T (n=32) All evaluable patients 12 (33)* 7 (26)* 19 (44) 13 (41) PD-L1 h igh 5/18 (28) 4/16 (25) 7/18 (39) 8/16 (50) PD-L1 l ow 7/25 (28) 3/16 (19) 12/25 (48) 5/16 (31) *pCR rate is calculated using UMVUE method when the final sample size of Simon's two-stage is changed.

Outcomes of high-risk prostate-specific antigen level during active surveillance with targeted and systematic prostate biopsy.

Journal of Clinical Oncology Braden Millan, Jaskirat Saini, Mitchell J. Hwang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.343

343 Background: National Comprehensive Cancer Network (NCCN) recommendations for very low to intermediate-risk prostate cancer (PCa) include active surveillance (AS). Patients who develop a prostate-specific antigen (PSA) level over 20 ng/mL during AS, however, are re-classified as NCCN high-risk and are recommended to undergo definitive management. In the past decade, the diagnostic accuracy for PCa has significantly improved with a combined approach to prostate biopsies (magnetic resonance imaging and ultrasound fusion targeting + systematic). This study aims to describe the outcomes of patients who continued AS following a PSA of 20 ng/mL or higher. Methods: Patient information and clinical data were obtained from a prospectively maintained database at the National Cancer Institute (NCT02594202). Patients on AS with a minimum of one subsequent combined biopsy (fusion + systematic) following a PSA of 20 ng/mL or higher were identified. Descriptive statistics were obtained using GraphPad Prism 10.1 (Boston, Massachusetts USA). Results: A total of 20 patients were identified, of whom 15 (67.7%) subsequently underwent definitive management. Patients had a median age of 72.0 [IQR 71-74.8] years, with a median of 13 [IQR 10-12] years on AS. In the continued AS cohort, the most recent PSA was below 20 ng/mL in two patients with a median of 22.9 ng/mL [IQR 15.2 -23.6], while repeat biopsy showed benign tissue or grade group (GG) 1 disease. In those who underwent definitive management, the last PSA on AS was a median of 23.2 ng/mL [IQR 21.9-32.8], with all patients having GG 2 or higher disease. Twelve patients underwent surgery and three external beam radiotherapy with long-term androgen deprivation therapy, within a median time of 2 mos [IQR 2.0 - 2.5 mos] after their last biopsy. For those who underwent surgery, 4 (33.3%) had GG upstaging, 2 (16.7%) had GG downstaging, while 6 (50.0%) had no change in overall GG on final pathology. The first post-operative PSA was undetectable in all but one patient. Conclusions: A PSA greater than 20 ng/mL is a high-risk feature that continues to have clinical significance during AS in the contemporary era of combined prostate biopsies. In our small cohort, one quarter of the patients remain on AS, while three-quarters of the patients underwent definitive management. GG upgrading occurred in one third of patients and therefore continued AS in these patients should be approached with caution and limited to those with benign findings or GG 1 disease on follow-up combined biopsy.

Determining optimal patient selection for high-intensity focused ultrasound (HIFU) for prostate cancer: Results from a single-institution cohort.

Journal of Clinical Oncology Kevin Shee, William Pace, Andrew W Liu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.362

362 Background: High-intensity focused ultrasound (HIFU) uses magnetic resonance imaging (MRI) and transrectal ultrasound to target areas affected by prostate cancer (PCa). HIFU has moderate PCa control outcomes with little impact on sexual or urinary side effects, but there is concern for disease recurrence and need for salvage treatment. Here we share institutional biopsy-proven recurrence and treatment failure outcomes following HIFU and identify clinicodemographic factors associated with adverse outcomes. Methods: All men who underwent robotic HIFU (Focal One) in 2021-2023 at the University of California, San Francisco and underwent 1-year post-procedure MRI-fusion biopsy were included. The primary outcome was treatment failure, defined as salvage treatment or metastases. Secondary outcomes were in-field recurrence, defined as Gleason Grade 2 (≥GG2) in the same region of HIFU treatment, overall recurrence, defined as ≥GG2 diagnosed anywhere in the prostate, and change in urinary and sexual function by International Prostate Symptom Score (IPSS) and Sexual Health Inventory for Men (SHIM) scores, respectively. Cox Proportional Hazards regression models and multivariable logistic regression and were used to estimate associations between clinical characteristics and outcome events. Results: Of 133 men who underwent HIFU, 110 had post-HIFU biopsy follow-up at median (IQR) of 12.5 (12-14) months. 18 (16%) had treatment failure, and median (IQR) time from recurrence to salvage treatment for 16 men was 3.5 (2-5) months. Cox proportional hazard regression showed pre-HIFU PSA to be associated with the risk of treatment failure (HR 1.14; 95% CI 1.05-1.24; p&lt;0.01). Additional modeling comparing clinically relevant PSA groupings (&lt;6, 6-10, and &gt;10) revealed a significant association between treatment failure and PSA &gt;10 (HR 5.35; 95% CI 1.54-18.57; p&lt;0.01), but not PSA 6-10 (HR 1.94; 95% CI 0.53-7.06). In-field and overall recurrence on 1-year biopsy was 42% and 50%, respectively. On logistic regression analysis, pre-HIFU Gleason Grade of 3 or greater (≥GG3) was associated with a higher likelihood of in-field recurrence (OR, 3.11; 95% CI, 1.13-8.56), and both ≥GG3 (OR 3.07; 95% CI 1.04-9.10, p=0.04) and higher PSA (OR 1.20; 95% CI 1.05-1.37; p&lt;0.01) were associated with a higher likelihood of overall recurrence. No significant differences were found for IPSS and SHIM scoring groups before and after HIFU. Conclusions: Treatment failure rate was 16%, and in-field and overall recurrence rates on biopsy one year after HIFU were 42% and 50%, respectively. Higher pre-HIFU PSA was associated with treatment failure and overall recurrence on biopsy, and ≥GG3 was associated with in-field and overall recurrence on biopsy. These findings emphasize the importance of careful patient selection for HIFU, which has potential for modest cancer control with minimal side effects in the appropriate PCa patient.

Inductive effect of charge transfer in ferroelectrics and plasmonic Ag heterojunctions for enhanced CO2 photoreduction

Applied Physics Letters Xiao Liu, Jicong Wang, Wenchao Tian et al. Feb 10, 2025 DOI: 10.1063/5.0254634

Converting carbon dioxide into fuel and chemicals by utilizing solar energy represents a cutting-edge approach to carbon recovery and energy renewal. The transfer behavior of photogenerated electrons and built-in electric field of photocatalysts greatly affect the efficiency of the photoreduction reaction. Herein, the heterostructures composed of bismuth sodium titanate (BNT) ferroelectrics and silver nanoparticles (Ag NPs) are constructed to promote the photocatalytic CO2 performance. The large spontaneous polarization of BNT optimizes the transfer dynamics of photoinduced electrons and holes and causes energy band bending with strong intrinsic electric field. With the aid of Ag NPs, the BNT@xAg heterojunctions exhibit intensified light absorption due to the phenomenon of localized surface plasmon resonance (LSPR), which extends the visible light absorption spectrum and strengthens charge transfer. The modified catalysts demonstrate improved charge separation capacity and notably prolonged electron lifetime up to 40.95 ns. The synergistic effect of LSPR and intrinsic polarization significantly boosts the photocatalytic efficiency together with ultrahigh CO product selectivity, which is outstanding among the ferroelectric and other representative photocatalysts. This study elucidates the photocatalytic enhancement mechanism of plasmonic Ag decorated BNT and offers an alternative route for the design of efficient catalysts.

Standalone ultrasound-based highly visualized volumetric spine imaging for surgical navigation

Scientific Reports Xinben Hu, Tianjian Liu, Zhengyuan Zhang et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89440-z

Gut microbiota as a biomarker for the efficacy of pembrolizumab in patients with advanced urothelial carcinoma treated in a prospective multicenter study.

Journal of Clinical Oncology Soufyan Annakib, Lucia Grenga, Catherine Dunyach-Remy et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.825

825 Background: Pembrolizumab (Pb) is a treatment (trt) for advanced urothelial carcinoma (aUC). In this study, we analyzed the fecal metaproteome of aUC patients (pts) to investigate the differences in the taxonomic and functional composition of the gut microbiome in responders (R) vs non-responders (NR) to pembrolizumab monotherapy as second-line trt. Methods: We designed a prospective multicenter study in France. Stool samples were collected before and nine weeks after the start of Pb, with a maximum follow-up of 36 weeks. Trt efficacy was evaluated using the Response Evaluation Criteria in Solid Tumors v1.1. Proteins were extracted from each sample and analyzed using high-resolution tandem mass spectrometry combined with liquid reverse phase chromatography. Raw data were interpreted without a priori assumptions. The R package Metacoder was used to analyze taxonomic diversity, while the mixOmics package was used to perform partial least squares discriminant analysis (sPLSDA) to reveal microbiota changes between R and NR pts. A Benjamini-Hochberg (BH)-corrected Wilcoxon test identified microbial functions with different frequencies in R and NR pts. A multivariate logistic regression analysis with Bonferroni correction was conducted to create a response-prediction classifier based on clinical variables and identified relevant microbial genera. The significance threshold was set at 5%. Results: From 2019 to 2022, 53 samples were taken from 34 different pts. Of these, 3 (8.8%) pts with complete response, 5 (14.7%) with partial response and 2 (5.9%) with stable disease were classified as R. Four (11.8%) deceased pts before response evaluation were excluded from the analysis. NR corresponded to disease progression in 20 pts (58.8%). No dysbiosis was detected. There were no statistically significant differences in alpha diversity over time or between R and NR. Beta diversity index showed microbiome stability at individual level during follow-up. sPLSDA at the genus level pooling all samples (before and after trt) showed a distinctive separation between R and NR (p ≤ 0.05). Of the genera contributing most to this separation, 4 genera were identified using logistic regression: Anaerostipes, Sutterella, Escherichia, Evtepia (adj. p ≤ 0.05). Functional composition analysis identified 31 signaling pathways that differ between R and NR. These signaling pathways were clustered highlighting 7 functions that differed between R and NR when modulated by Pb. Host function analysis identified the “response to external biotic stimuli” signaling pathway significantly associated to R (BH adj p-value ≤0.05). Conclusions: The composition of the gut microbiome and metabolic functions differed between R and NR pts with aUC under Pb. The genera Anaerostipes , Sutterella, Escherichia and Evtepia could be biomarkers for the efficacy of pembrolizumab. Clinical trial information: NCT03584659 .

Pathogenic germline variant prevalence and genetic testing outcomes in patients with urothelial carcinoma.

Journal of Clinical Oncology Eugene Oh, Piroz Bahar, Ye Chua et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.741

741 Background: Urothelial carcinoma (UC) is rarely attributed to hereditary causes, but recent studies suggest inherited factors may play a larger role. Current guidelines recommend considering genetic evaluation in patients with bladder cancer diagnosed at &lt;50 years old or a personal or family history of Lynch Syndrome-associated cancers. However, the full pathogenic germline variant landscape and optimal genetic evaluation criteria in UC remain poorly understood. In this study, we report the genetic testing outcomes and clinicopathologic characteristics of patients with UC who underwent genetic evaluation. Methods: A retrospective analysis of all patients with UC who underwent genetic evaluation and testing at the University of Michigan Cancer Genetics Clinic between 2002 and 2024 was performed. Patients who did not have a UC diagnosis code or did not undergo germline testing were excluded. Genetic testing outcomes, variant prevalence and characterization, and associated clinicopathologic features were recorded. Fisher’s Exact test was used to compare clinicopathologic factors between individuals found to have a pathogenic or likely pathogenic variant (PV/LPV) vs. those with negative or uninformative testing. Results: Among 151 patients referred to cancer genetics, 129 underwent genetic testing. Median age at diagnosis was 59 (IQR: 48-68). Most patients (58%) had non-muscle invasive disease at initial diagnosis; 26% had muscle invasive disease, 9% had metastatic disease, and 7% were unknown. Pure urothelial histology was most frequent (71%). A majority (83%) had primary tumor location in the bladder. The most common reasons for referral to genetic counseling were personal history of multiple cancers (58%), diagnosis at perceived younger age (19%), and suspicion for a hereditary syndrome based on syndromic features (9%). Among all tested patients, 35 (27%) had a confirmed PV/LPV; 18 (14%) had a variant of unknown significance (VUS) only. Most frequent PV/LPV genes were MSH2 (n=8, 6%), BRCA2 (n=5, 4%), CHEK2 (n=4, 3%), APC (n=4, 3%), and MUTYH (n=4, 3%). There were no statistically significant differences in testing outcomes based on age of diagnosis (&lt;65 vs &gt;65, p=0.83; &lt;55 vs &gt;55, p=0.16; &lt;45 vs &gt;45, p=0.61), primary tumor location, stage at initial diagnosis, personal history of other cancers, or first-degree family history of urothelial cancer. Oncoprint visualization will be presented. Conclusions: Among patients with UC referred to cancer genetics who had genetic testing, 27% had a confirmed PV/LPV, although this cohort was a selected population. Age threshold and traditional clinicopathologic features were not associated with genetic testing results. These findings may suggest a broader use of genetic evaluation in UC. Future studies should determine the optimal genetic evaluation criteria in UC given the impact on cascade testing and potential therapeutic implications.

Late onset of apalutamide-related skin toxicity in Black men with advanced prostate cancer: A diverse real-world analysis.

Journal of Clinical Oncology Chen H Yong, Alaa Ahmed Genidy Aly, Debra Hannah Josephs et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.23

23 Background: Apalutamide (APA)- related skin toxicity is a common adverse reaction of varying incidence by ethnicity 1 . We have limited data on APA-related skin toxicity in Black men due to under-representation in clinical trials 2 . This real-world analysis evaluates APA-related skin toxicity and its differential impact across Black and White men in an ethnically diverse population at two high-volume cancer centers in London, United Kingdom. Methods: We investigated 120 prostate cancer patients treated with APA between 2021 and 2023. Skin toxicity incidence and grading, time to onset and drug discontinuation rates were examined. Adverse event causality was attributed by treating physicians and graded by the Common Terminology Criteria for Adverse Events v5.0 based on body surface area involvement. The cumulative incidence of APA-related skin toxicity and APA discontinuation rates were estimated by Gray’s method. Results: 111 patients were included in our analysis, represented by 35 (31.5%) Black and 76 White men (68.4%). 18 men (16.2%) had pre-existing autoimmune or skin disease. 108 men (97%) commenced APA at 240 mg. At 24-month follow up, APA-related skin toxicity of any grade and Grade 3, were seen in 23 (23%) and 12 men (12%) respectively. There was no significant difference in skin toxicity incidence or severity between Black and White men (Table). The median time to skin toxicity was 179 and 84 days in Black and White men respectively, with late onset (&gt;6 months) events more commonly seen in Black men. APA discontinuation rate due to skin or other Grade 3 toxicity was similar (24-month, 11.4% in Black vs 9.2% in White men). Based on multivariable competing risk analysis, skin or autoimmune disease, or eosinophil count at baseline had no significant impact on incidence or severity of skin toxicity. Conclusions: Late onset of APA-related skin toxicity is seen more commonly in Black men, thus requires clinical vigilance and monitoring. There is no significant ethnicity disparity in incidence or severity for APA-related skin toxicity. No significant risk factors for incidence and severe skin toxicity were identified. Cumulative incidence of APA-related skin toxicity at 6 and 24 months. Skin Toxicity Ethnicity 6-months 24-months p-value Any grade 0.851 White 14% 21% Black 11% 25% Grade 3 0.954 White 9.2% 11% Black 2.9% 13%

Effects of integrating palliative care on the uptake of advance care planning among elderly patients with advanced genitourinary cancers.

Journal of Clinical Oncology Phichai Chansriwong, Tanin Tiyanont, Siriporn Semsarn et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.49

49 Background: Integrating palliative care (PC) into oncology has been demonstrated to significantly enhance the quality of life for these patients and facilitating patient decision-making, particularly concerning advance care planning (ACP). ACP is a structured process that ensures patients' values and preferences regarding the end-of-life care are respected, and frequently results in the completion of advance directives (AD). This study aims to evaluate the impact of PC on the uptake of ACP among patients with advanced GU cancers. Methods: A retrospective analysis was conducted using a claims database from Ramathibodi Hospital, encompassing elderly cancer patients who had a medical claim for death between Jan1, 2016, and Dec31, 2021 included 1,013 patients, with 532 males, and a mean age of 72.37 years (60.5-99). Among these, 215 patients (21.2%) received integrated palliative care (PC). 102 patients with GU malignancies, including 44 with TCC, 36 with prostate cancer, 22 with RCC. Of these, 22 patients (21.6%) were treated with PC. The primary outcomes measured were the completion rates of ACP and AD. Secondary outcomes included the utilization of treatments in the 6 months preceding death. Comparative analyzes were performed between the PC and UC groups to assess the impact of PC on these outcomes. Results: Regarding ACP, 78.9% of patients in the UC group engaged in ACP, with a median time of 4.5 days (range: 0-324 days) before death. In contrast, 100% of patients in the PC group engaged in ACP, with a median time of 259.7 days (range: 0-2,077 days) before death. 46.5% of patients in the PC group completed AD, whereas no patients in the UC group completed AD. Patients receiving palliative chemotherapy within 30 days before death were significantly lower in the PC group, with an odds ratio of 3.30 (P &lt; 0.001). In the 6 months preceding death, the PC group exhibited significantly lower ER visits (P = 0.011), inpatient admissions (P &lt; 0.001), and total hospital visits (P = 0.002) compared to the UC group. Conclusions: Integrating palliative care into the oncology treatment framework significantly improves the uptake of ACP among patients with advanced GU cancers. This comprehensive approach not only reduces the utilization of aggressive treatments near the end of life, but also enhances the alignment of medical care with patients' values and preferences. Clinical trial information: COA. MURA2023/258 .

Peculiar spin Hall magnetoresistance in polycrystalline WTe2/Ni80Fe20 heterostructures

Applied Physics Letters Zong-kui Tian, Zi-yan Luo, Jun-jie Guo et al. Feb 10, 2025 DOI: 10.1063/5.0229028

Charge–spin interconversion is a key issue in spintronics. It gives rise to a series of new phenomena, such as spin Hall magnetoresistance (SMR). In the present work, we report the peculiar SMR behaviors in heterostructures composed of polycrystalline WTe2 nanoplate and Ni80Fe20(Py) film. We observe a negative SMR, which is contrary to the positive SMR usually measured in heavy metal/ferromagnet bilayers. We further observe a transition from negative to positive SMR with increasing thickness of the WTe2 layer, as well as SMR sign reversal with increasing temperature in heterostructures with thicker WTe2. The peculiar SMR behaviors in polycrystalline WTe2/Py heterostructures are attributed to the interface-induced spin current and its competition with the spin Hall-induced spin current. The findings in this work offer a fundamental input for the future exploitation of heterostructures based on two-dimensional transition metal dichalcogenides.

Adult ADHD predicts intimate partner violence perpetration and victimization irrespective of gender and age

Scientific Reports Johannes Merscher, Steffen Barra, Anika May Xander et al. Feb 10, 2025 DOI: 10.1038/s41598-024-74222-w

Abstract Understanding the determinants of intimate partner violence (IPV) from perpetrator and victim perspectives has become a major objective of behavioral science. Empirical evidence suggests that adults at risk for Attention-Deficit/Hyperactivity Disorder (ADHD), compared to the general population, tend to have more conflictual partnerships, and the presence of ADHD increases the risk of aggressive behavior. Possible influences of gender have not been sufficiently investigated yet. Using data from an anonymous online survey, this study examined the relationship between ADHD and IPV in 316 male and female individuals with (n = 131) and without (n = 185) ADHD. Multiple linear regression analyses showed that adults at risk for ADHD had more frequently become both victims and perpetrators of IPV compared to the healthy control group. ADHD achieved significant incremental variance over gender and age. Thus, the presence of ADHD seems to be an important risk factor for IPV irrespective of gender and age. Accordingly, research and treatment approaches focusing on ADHD must not neglect the risk of IPV among patients but should offer specific psychological support.

Bone metastases and use of bone protective agents (BPA) for metastatic renal cell carcinoma (mRCC): A contemporary national real-world analysis.

Journal of Clinical Oncology Braden Millan, Sunita Ghosh, Naveen S. Basappa et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.490

490 Background: Bone Metastases (BM) occur in approximately 30% of mRCC patients (pts) with evidence suggesting that they portend a worse prognosis. Systemic therapies such as tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICI) are felt to be active in these pts, with radiation therapy (RT) often employed for BM-directed treatment. The evidence for and use of BPAs, such as bisphosphonates and denosumab, is limited in the current ICI era. We investigated the outcomes of mRCC pts with BM and use of BPA in a contemporary real-world cohort. Methods: We analyzed data collected from the prospectively maintained, multi-institutional Canadian Kidney Cancer Information System (CKCis). Patients with clear cell mRCC treated between January 2011-June 2023 were included. Outcomes were compared between BM+ and BM- pts using Cox proportional hazards models. Kaplan-Meier estimates were used to assess time to treatment failure (TTF) and overall survival (OS) adjusted by IMDC criteria. Results: Of 2,307 patients with clear cell mRCC, 893 (39%) had BM+, of whom 691 (77%) underwent RT, and 139 (16%) received a BPA. Median follow-up was longer for BM- patients (34.6 vs 29.1 mos). Significant differences were noted in Karnofsky performance status (&gt; 80%: 84% vs 78%), IMDC risk group (intermediate/poor: 76% versus 82%) use of RT (35% vs 78%), and use of BPAs (2% vs 16%) between BM- vs BM+ pts (all p &lt; 0.05). In our cohort, first-line treatment in BM+ pts was monotherapy TKI (67%), doublet ICI (20%), and combination TKI+ICI (13%). Median TTF was similar in BM- vs BM+ pts: 9.6 vs 8.6 mos (HR 0.92; 95% CI 0.91-1.02). However, median OS was higher in BM- vs BM+ pts: 57.6 vs 35.8 mos (HR 0.67; 0.58-0.76; p&lt;0.0001); this was consistent irrespective of type of systemic therapy. In BM+ pts, those who did not receive BPAs had a lower TTF (7.9 vs 13.4 mos) and OS (34.0 vs 46.0 mos); however, these were not statistically different when adjusted by IMDC criteria (TTF HR 1.2; 0.95-1.51 and OS HR 1.12; 0.85-1.46). There was no significant difference in TTF (HR 0.89; 0.72-1.10) or OS (HR 0.94; 0.73-1.22) in BM+ pts selected to receive RT. Conclusions: BM remain a poor prognostic factor in mRCC in this contemporary cohort of patients. While BPA use was limited, we observed no improvement in TTF or OS in BM+ pts with their use. These data warrant further investigation of BPA in mRCC including assessment of SREs and potential complications.

Nectin-4 and Trop-2 expression as potential therapeutic target in collecting duct carcinoma: Preliminary results from the CICERONE trial (NCT05372302).

Journal of Clinical Oncology Giuseppe Procopio, Alessandro Rametta, Marco Stellato et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.587

587 Background: Collecting Duct Carcinoma (CDC) represents 1% of all renal cell carcinomas (RCC) and is characterized by aggressive clinical behavior and a particularly dismal prognosis. Cabozantinib and platinum-based chemotherapy are active therapeutic options, but survival remains poor with no novel agents approved for the treatment of metastatic disease. Antibody-Drug Conjugate (ADC) targeting Nectin-4 and TROP-2 are dramatically changing the therapeutic landscape of Urothelial Carcinoma (UC). Given the biological and clinical similarities between CDC and UC, we evaluated Nectin-4 and TROP-2 expression in CDC. Methods: CDC tissue samples were collected from patients enrolled in the CICERONE study (NCT05372302), a multicentric trial that aims to define the transcriptomic profile of CDC with the goal of changing the paradigm of CDC management by using biology-driven treatments. Nectin-4 and TROP-2 are surface proteins involved in cell adhesion and proliferation. Their expression was assessed by immunohistochemistry (IHC) using a validated assay with a Nectin-4 antibody (clone M22-321b41.1) and a TROP-2 antibody (Ab227689 by Abcam).Staining area was quantified as a percentage (0–100%) and considered positive if &gt;10% of the tumor surface was stained. Staining intensity was dichotomized into positive and weakly positive, based on a clear distinction from the negative control. Results: 59 tissue samples from patients with diagnosis of CDC were considered eligible after centralized histological review. Fresh or archival tumor tissue was collected from either primary lesion or metastatic sites biopsies at baseline before the start of systemic therapy. Preliminary results demonstrated that Nectin-4 was expressed in 24 out of 59 samples (41%), while TROP-2 positivity was observed in 58/59 cases (98%). Conclusions: CDC appears to be a unique kidney tumor, which lies between UC and RCC clinically and biologically. Here we report for the first time the expression of two potential therapeutic targets in metastatic CDC, Nectin-4 and TROP-2, confirming the similarities between CDC and UC.Based on this encouraging data, along with the interesting results from EV-302 trial, we hypothesize that pembrolizumab in combination with Antibody-Drug Conjugate (ADC) could be active in mCDC and this combo will be assessed in the phase II RePRINT trial (NCT06302569). Clinical trial information: NCT05372302 .